Skip to main content
Clinical Trials/NCT07362537
NCT07362537
Recruiting
Not Applicable

Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe Acute Respiratory Distress Syndrome: a Randomized Controlled Trial

Southeast University, China1 site in 1 country40 target enrollmentStarted: January 20, 2026Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
Southeast University, China
Enrollment
40
Locations
1
Primary Endpoint
Cumulative Enteral Nutrition intake to target ratio

Overview

Brief Summary

This pilot study is aimed to compare and assess the impact, safety, and practical utility of gastric versus postpyloric feeding in moderate to severe ARDS patients with prone position ventilation. Patients included will be randomly assigned to receive enteral nutrition either through a nasogastric tube or a nasojejunal tube. The primary endpoint is the achievement of enteral nutrition goals. Secondary endpoints include the incidence of hospital-acquired infections, the number of ventilator-free days within 28 days, ICU length of stay, ICU mortality, 28-day mortality, 60-day mortality rates, the incidence of enteral nutrition intolerance, and the rate of enteral nutrition intake.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ARDS patients who meet the Berlin criteria for ARDS and have a P/F ratio ≤ 200mmHg.
  • Patients receiving invasive mechanical ventilation and clinically judged to require prone ventilation, with an anticipated daily prone positioning time of ≥12 hours and a duration of prone ventilation therapy of ≥3 days.
  • Patients planned to receive enteral nutrition.
  • Age ≥18 and ≤85 years.
  • Consent to sign an informed consent form.

Exclusion Criteria

  • Contraindications to enteral nutrition, such as severe intestinal ischemia, active upper gastrointestinal bleeding, high-output intestinal fistula without a distal feeding route, abdominal compartment syndrome, severe diarrhea, intestinal obstruction, etc.
  • Presence of shock with hemodynamic instability (norepinephrine or equivalent vasopressor dosage ≥0.5ug/kg.min) or tissue hypoperfusion (lactate \>3mmol/L).
  • Life-threatening hypoxemia, hypercapnia, and acidosis.
  • Inability to tolerate prone ventilation (e.g., pregnant women, limb contractures, recent fractures, recent thoracic or abdominal surgery, pacemaker insertion within 48 hours, spinal instability, pelvic fractures, facial fractures, anticipated difficult airway).
  • Conditions preventing nasogastric or nasojejunal tube placement (e.g., esophageal rupture, severe esophageal varices).
  • Anticipated inability to start enteral nutrition within 48 hours.
  • Use of prokinetic agents within 48 hours prior to starting enteral nutrition.
  • Enteral nutrition via gastrostomy or jejunostomy.
  • Expected ICU stay or survival time less than 3 days.
  • Patients refusing further resuscitative treatment.

Arms & Interventions

Post-pyloric feeding group

Experimental

Enteral nutrition through nasojejunal tube

Intervention: enteral nutrition through nasojejunal tube (Procedure)

Gastric feeding group

Active Comparator

Enteral nutrition through nasogastric tube

Intervention: enteral nutrition through nasogastric tube (Procedure)

Outcomes

Primary Outcomes

Cumulative Enteral Nutrition intake to target ratio

Time Frame: follow-up till 7-day

The ratio of total calorie and protein intake through EN to target calorie and protein respectively.

Secondary Outcomes

  • Incidence of new Infections(follow-up till 28-day)
  • Ventilator-free days within 28 days(follow-up till 28-day)
  • ICU Length of Stay(up to 24 weeks)
  • ICU Mortality Rate(up to 24 weeks)
  • 28-Day Mortality Rate(28 days)
  • 60-Day Mortality Rate(60 days)
  • Incidence Rate of Enteral Nutrition Intolerance(28 days)
  • Daily Enteral Nutrition Intake Rate(7 days)

Investigators

Sponsor
Southeast University, China
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ling Liu

Professor

Southeast University, China

Study Sites (1)

Loading locations...

Similar Trials